What Klaria Pharma Holding does

Klaria Pharma Holding AB (publ) is a Swedish pharmaceutical company headquartered in Uppsala that develops and commercializes innovative drug products using its proprietary alginate-based transmucosal film technology. The platform film adheres to the oral mucosa for 3–5 minutes before fully dissolving, transferring the active pharmaceutical ingredient directly into the bloodstream and bypassing the gastrointestinal tract — a delivery profile the company emphasizes as superior to starch-based films and sprays, where most of the drug is swallowed. Klaria's product strategy targets molecules that are not orally bioavailable and currently require injection, where the technology can deliver a superior patient experience at lower cost.

The company's pipeline includes Sumatriptan Alginate Film (KL-00119) for acute migraine — particularly useful for the ~80% of migraine patients who experience nausea during attacks — which received EU market authorization in 2024 and is planned for European launch in 2026 via an exclusive licensing agreement with CNX Therapeutics. Additional pipeline programs include Adrenaline Alginate Film for anaphylactic shock (R&D collaboration with Imbrium Therapeutics), Sirolimus Alginate Film for organ transplant rejection prevention (development collaboration with FluiMed GmbH), Naloxone Alginate Film for opioid overdose reversal, and a Cannabinoid Alginate Film program covering 85 molecules under perpetual license from UppsalaGruppen Medical AB. The underlying technology is licensed exclusively from UppsalaGruppen Medical AB and protected by multi-generation patents, with a third-generation sumatriptan patent application that could extend exclusivity to 2045.

Klaria operates as a pre-commercial, capital-light pharmaceutical development company. It generates revenue through licensing royalties, R&D collaboration milestones, and non-dilutive EU grants (notably a 2018 Horizon 2020 grant of approximately 21 MSEK), and it distributes products through licensing partnerships rather than a direct sales force. FY2025 net sales of 9.0 MSEK (up from 2.2 MSEK in 2024) against a net loss of -38.9 MSEK (improved from -47.7 MSEK) reflect a company still in investment phase, with BDO LLP engaged to source additional geographic partners and a 2026 EU commercial launch as the principal near-term catalyst.

Name

Klaria Pharma Holding

Legal name

Klaria Pharma Holding AB (publ)

Website

https://klaria.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Klaria Pharma Holding is a Swedish pharmaceutical company developing a proprietary alginate transmucosal film for oral-mucosa drug delivery, with a lead EU-approved Sumatriptan migraine film launching in 2026 and pipeline programs in anaphylaxis, transplant rejection, opioid overdose, and cannabinoids.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Transmucosal Drug Delivery

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

Keywords

• Transmucosal drug delivery
• Alginate film technology
• Pharmaceutical drug development
• Buccal drug delivery
• Migraine therapeutics

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Licensing: Licensing agreements with partners such as CNX Therapeutics for EU market distribution of Sumatriptan Alginate Film. Klaria retains intellectual property while partners handle commercialization in licensed territories.
2. R&D Collaboration Milestones: Milestone payments from R&D collaborations with partners such as Imbrium Therapeutics for Adrenaline Alginate Film development, and FluiMed GmbH for Sirolimus Alginate Film development.
3. EU Research Grants: Non-dilutive funding from EU Horizon 2020 program. Klaria received EUR 2,031,574.13 (approximately 21 MSEK) grant for KL-00119 migraine project.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Klaria develops and licenses pharmaceutical products based on its proprietary alginate transmucosal film technology, which delivers active drug substances directly into the bloodstream through the oral mucosa, bypassing the gastrointestinal tract. Its portfolio includes Sumatriptan Alginate Film (migraine, EU-approved, launching 2026 with CNX Therapeutics), Adrenaline Alginate Film (anaphylaxis), Sirolimus Alginate Film (transplant rejection), Naloxone Alginate Film (opioid overdose), and Cannabinoid Alginate Film (pain). The company commercializes through licensing and co-development partnerships rather than direct sales.

Product overview

Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops novel drugs using its proprietary Alginate Transmucosal Film technology. The technology enables drugs to be delivered through the oral mucosa directly into the bloodstream, bypassing the gastrointestinal tract. This is particularly valuable for drugs that are not orally available and must currently be given by injection. The company is developing a portfolio of alginate film products: Sumatriptan Alginate Film (KL-00119) for migraine, Adrenaline Alginate Film for anaphylactic shock, Sirolimus Alginate Film for transplant rejection prevention, Naloxone Alginate Film for opioid overdose, and Cannabinoid Alginate Film for pain management. The lead product Sumatriptan Alginate Film has received EU market authorization and is planned for launch in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Sumatriptan Alginate Film (KL-00119) Novel transmucosal film formulation delivering sumatriptan directly through the oral mucosa for acute treatment of migraine attacks. Bypasses gastrointestinal absorption, which is especially beneficial for the approximately 80% of migraine patients who also experience nausea during attacks. Licensed to CNX Therapeutics for commercialization in the EU.
• Adrenaline/Epinephrine Alginate Film Epinephrine formulated in Klaria's alginate film for emergency treatment of anaphylactic shock. Designed to replace bulky auto-injector pens (e.g., EpiPen) with a small, easy-to-carry, needle-free, simple-to-administer film. The successful formulation of the unstable adrenaline molecule demonstrates the capability of Klaria's transmucosal platform.
• Sirolimus Alginate Film Immunosuppressant film delivering sirolimus via the oral mucosa for prevention of organ rejection in solid organ transplantation. Transmucosal delivery bypasses metabolism-driven variability in sirolimus efficacy and safety between individual patients.
• Naloxone Alginate Film Opioid overdose antidote film formulation delivering naloxone through the oral mucosa with rapid absorption directly into the bloodstream to counteract respiratory depression and prevent fatal outcomes from opioid overdose.
• Cannabinoid Alginate Film Pain medication film formulation using cannabinoids, developed under exclusive license from UppsalaGruppen Medical AB covering 85 different molecules. Targets pain patients and neurological conditions including epilepsy and cancer-related pain.

Quantifiable outcome

• Film stays attached to oral mucosa for 3-5 minutes before completely dissolving
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• CNX TherapeuticscoreChannel Partner/ Reseller/ Distributor · 23 December 2025EU licensing partner for Sumatriptan Alginate Film. CNX Therapeutics is preparing for expected product launch in Europe in 2026, including ongoing large-scale manufacturing of the product.
• BDO LLP (UK Life Sciences & Healthcare M&A Team)coreStrategic or Co-development Partner · 23 December 2025Collaboration with BDO's UK Life Sciences & Healthcare M&A team to support business development and potential partnerships for sumatriptan products in key markets. BDO is helping identify and establish contact with potential partners for strategically important markets. All potential options including licensing or divestitures that can maximize shareholder value will be considered.
• Imbrium TherapeuticsminorStrategic or Co-development Partner · 15 May 2023R&D collaboration for Adrenaline Alginate Film. Klaria received payment of 2.6 MSEK from Imbrium Therapeutics within this collaboration.
• FluiMed GmbHminorStrategic or Co-development Partner · 5 May 2022Agreement to develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection. Development collaboration for this specific therapeutic indication.
• UppsalaGruppen Medical ABcoreTechnology or Integration · 21 October 2015Licensor of patented alginate film technology. Klaria holds exclusive license for the technology. Also provides exclusive and perpetual license for cannabinoid film development covering 85 different molecules, with royalties of 3% on net revenues.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Zosano Pharma: Zosano developed a transdermal microneedle patch for sumatriptan (Qtrypta) targeting acute migraine — the closest direct competitor to Klaria's transmucosal sumatriptan film in both indication and alternative-delivery approach.
• Aquestive Therapeutics: Aquestive is a specialty pharma built around its PharmFilm oral soluble film technology with multiple approved products (including CNS and allergy indications) — directly comparable transmucosal film platform addressing similar pharmaceutical partners and patient use cases.
• IntelGenx Technologies: IntelGenx is an oral thin-film drug delivery platform company that has commercialized multiple buccal/sublingual film products (e.g., Rizafilm for migraine), making it a direct competitor on both technology and migraine indication.
• Neurelis: Neurelis developed VALTOCO, a nasal diazepam spray for seizure rescue — analogous to Klaria's strategy of reformulating injectable-only drugs into patient-friendly non-oral delivery formats for acute/emergency indications.
• BioDelivery Sciences International: BDSI developed and commercialized buccal film products (e.g., Bunavail for opioid dependence, Belbuca for pain) and represents a direct buccal/transmucosal film peer in pharma applications.

Broad incumbents

• Teva Pharmaceutical Industries: Teva markets the authorized generic EpiPen and other epinephrine auto-injectors — the dominant incumbent Klaria's adrenaline alginate film is explicitly designed to disrupt.
• Pfizer (Biohaven integration): Pfizer acquired Biohaven's CGRP migraine franchise (Nurtec, etc.) and is the dominant branded migraine competitor that Klaria's transmucosal sumatriptan would need to differentiate against in any future US launch.
• Harmony Biosciences: Harmony Biosciences markets Wakix and other CNS/migraine therapies, making it a broad incumbent in the migraine specialty space where Klaria plans to compete with its sumatriptan film.
• Emergent BioSolutions: Emergent's Narcan nasal naloxone is the established non-injectable opioid overdose reversal product and the closest incumbent comparator to Klaria's Naloxone Alginate Film pipeline asset.

Others

• Monosol Rx (acquired by Curia): Monosol Rx was a pioneer in pharmaceutical oral soluble films (suboxone film, etc.) and was acquired by Contract Pharmaceuticals / Curia; relevant as an enabling CDMO/technology peer in the oral film drug delivery ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Klaria Pharma Holding